Radiology artificial intelligence firm Brainomix raises $18M, expands in US

Radiology artificial intelligence firm Brainomix has raised $18 million in new funds and is expanding in the U.S., the company announced Thursday. 

Michalis Papadakis, PhD, founded the organization in 2010 while working as a scientific director at the University of Oxford. Brainomix specializes in AI-powered software focused on stroke and lung fibrosis, with its solutions deployed at over 300 hospitals and impacting 1.5 million patients. 

“Prominent” health-tech investors co-led the Series C financing round, including Parkwalk Advisors, the United Kingdom’s largest growth EIS fund manager, and Germany’s Boehringer Ingelheim Venture Fund. They’ll use the money to accelerate commercial expansion in the U.S. and advance its AI portfolio into new clinical areas.

“Brainomix has demonstrated an unparalleled track record of successfully delivering AI solutions into stroke clinical practice, and they are now doing it again in lung fibrosis,” Oliver Reuss, PhD, Boehringer Ingelheim Venture Fund investment manager and director of the AI firm’s board, said in a statement March 20. “As a strategic investor with a shared vision to enhance care for lung disease, we believe Brainomix has the potential to improve the identification and access to treatment for people with lung fibrosis.”

The company operates across 20 countries including the U.S. Its core platform, Brainomix 360 Stroke, automates validated imaging biomarkers to improve diagnoses and treatment decisions. It now boasts a staff of 75, with plans to expand operations in Oxford and globally. Brainomix’s e-Lung technology is cleared by the U.S. Food and Drug Administration and is utilized for accurately predicting the progression of lung fibrosis. Boehringer Ingelheim—a German research and pharmaceutical firm—is currently evaluating the real-world impact of e-Lung on improving diagnosis of, and treatment for, lung fibrosis.